Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

Stephen M. Strakowski, Jacqueline L. Johnson, Melissa P. DelBello, Robert M. Hamer, Alan I. Green, Mauricio Tohen, Jeffrey A. Lieberman, Ira Glick, Jayendra K. Patel, Jeffrey Lieberman, Diana Perkins, Joseph Patrick McEvoy, Cecil Charles, Richard Keefe, Robert B. Zipursky, Zafiris J. Daskalakis, Alan I. Green, Charles B. Nemeroff, Robin Murray, Tonmoy SharmaRaquel E. Gur, Bruce Cohen, Franca Centorrino, R. S. Kahn, Wayne Goodman, John Kuldau, Anthony J. Rothschild, John De Quardo, Gary Tollefson, Todd Sanger

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.

Original languageEnglish (US)
Pages (from-to)161-169
Number of pages9
JournalSchizophrenia Research
Volume78
Issue number2-3
DOIs
StatePublished - Oct 15 2005

Keywords

  • First-episode psychosis
  • Functional outcome
  • SF-26
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode'. Together they form a unique fingerprint.

  • Cite this

    Strakowski, S. M., Johnson, J. L., DelBello, M. P., Hamer, R. M., Green, A. I., Tohen, M., Lieberman, J. A., Glick, I., Patel, J. K., Lieberman, J., Perkins, D., McEvoy, J. P., Charles, C., Keefe, R., Zipursky, R. B., Daskalakis, Z. J., Green, A. I., Nemeroff, C. B., Murray, R., ... Sanger, T. (2005). Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research, 78(2-3), 161-169. https://doi.org/10.1016/j.schres.2005.04.017